Potential Future of New Glutamate Agonists and Antagonists Development

Author(s): Dariusz Matosiuk*

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 18 , Issue 4 , 2018

Become EABM
Become Reviewer

Graphical Abstract:


Receptors of glutamic acid are known for over 30 years for their action and for about 20 years for their structure. Presence of at least three classes of ionotropic receptors was confirmed at the beginning of 80’. Recognition of the sequence and first cloning were done at the beginning of 90’. In 1994 ligand binding site was recognized at the junction of two subunits S1-S2 in the ligand-binding domain.

Since then, many subtypes of ionotropic and metabotropic glutamate receptors were recognized, together with their localization and functions.

In the meantime numerous orthosteric ligands, both agonists and antagonists were developed especially for NMDA ion channels. Their usefulness as drugs was rather low, due to the involvement in the excitatory tract. More interest was focused on metabotropic receptors, which are GPSR’s and can be modulated both by orthosteric and allosteric modulators.

It seems like allosterism could be considered as promising future for glutamate receptors and ion channels, especially when first allosteric negative modulators of the mGluR2 went close into the clinical trial.

Keywords: iGluR, mGluR, NMDA, AMPA, KA, AMPA auxiliary proteins, allosteric mGluR PAM and NAM modulators.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 17 July, 2018
Page: [506 - 520]
Pages: 15
DOI: 10.2174/1871520618666180404125041
Price: $65

Article Metrics

PDF: 34